EP1794315A4 - Verfahren zur nutzung neuer zielgene in verbindung mit immunvermittelten krankheiten - Google Patents

Verfahren zur nutzung neuer zielgene in verbindung mit immunvermittelten krankheiten

Info

Publication number
EP1794315A4
EP1794315A4 EP05787813A EP05787813A EP1794315A4 EP 1794315 A4 EP1794315 A4 EP 1794315A4 EP 05787813 A EP05787813 A EP 05787813A EP 05787813 A EP05787813 A EP 05787813A EP 1794315 A4 EP1794315 A4 EP 1794315A4
Authority
EP
European Patent Office
Prior art keywords
immune
utilization
methods
target genes
mediated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05787813A
Other languages
English (en)
French (fr)
Other versions
EP1794315A2 (de
Inventor
Riikka Lund
Riitta Lahesmaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP10162955A priority Critical patent/EP2386653A3/de
Publication of EP1794315A2 publication Critical patent/EP1794315A2/de
Publication of EP1794315A4 publication Critical patent/EP1794315A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05787813A 2004-09-16 2005-09-16 Verfahren zur nutzung neuer zielgene in verbindung mit immunvermittelten krankheiten Withdrawn EP1794315A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10162955A EP2386653A3 (de) 2004-09-16 2005-09-16 Verfahren zur Verwendung neuer Target-Gene, die im Zusammenhang mit immunvermittelten Krankheiten stehen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20041204A FI20041204A0 (fi) 2004-09-16 2004-09-16 Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
PCT/FI2005/050320 WO2006030071A2 (en) 2004-09-16 2005-09-16 Methods for the utilization of novel target genes related to immune-mediated diseases

Publications (2)

Publication Number Publication Date
EP1794315A2 EP1794315A2 (de) 2007-06-13
EP1794315A4 true EP1794315A4 (de) 2009-11-18

Family

ID=33041540

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10162955A Withdrawn EP2386653A3 (de) 2004-09-16 2005-09-16 Verfahren zur Verwendung neuer Target-Gene, die im Zusammenhang mit immunvermittelten Krankheiten stehen
EP05787813A Withdrawn EP1794315A4 (de) 2004-09-16 2005-09-16 Verfahren zur nutzung neuer zielgene in verbindung mit immunvermittelten krankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10162955A Withdrawn EP2386653A3 (de) 2004-09-16 2005-09-16 Verfahren zur Verwendung neuer Target-Gene, die im Zusammenhang mit immunvermittelten Krankheiten stehen

Country Status (4)

Country Link
US (1) US7989172B2 (de)
EP (2) EP2386653A3 (de)
FI (1) FI20041204A0 (de)
WO (1) WO2006030071A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101306A1 (en) * 2006-03-07 2007-09-13 Telethon Institute For Child Health Research Method for diagnosing and/or predicting the development of an allergic disorder and agents for treating and/or preventing same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088199A2 (en) * 2000-05-18 2001-11-22 Genetics Institute, Llc Identification and modulationof of a t helper-1 and t helper-2 cells

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0562025B1 (de) 1990-12-06 2001-02-07 Affymetrix, Inc. (a Delaware Corporation) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5677195A (en) 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
EP0730663B1 (de) 1993-10-26 2003-09-24 Affymetrix, Inc. Felder von nukleinsaeuresonden auf biologischen chips
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US6228575B1 (en) 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
ATE260989T1 (de) 1997-12-19 2004-03-15 Affymetrix Inc Erkenntnisse der genomforschung für die suche nach neuartigen wirkstoffen
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP5015373B2 (ja) 1998-04-08 2012-08-29 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 改良表現型を得るための方法及び手段
WO1999057130A1 (en) * 1998-05-05 1999-11-11 Gene Logic, Inc. A process to study changes in gene expression in t lymphocytes
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US8048672B2 (en) * 1999-06-02 2011-11-01 President And Fellows Of Harvard College T-bet compositions and methods of use thereof
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
WO2002028999A2 (en) 2000-10-03 2002-04-11 Gene Logic, Inc. Gene expression profiles in granulocytic cells
BRPI0115814B8 (pt) 2000-12-01 2021-05-25 Europaeisches Laboratorium Fuer Molekularbiologie Embl moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas
US20030099963A1 (en) * 2000-12-22 2003-05-29 Morris David W. Novel compositions and methods in cancer associated with altered expression of TBX21
AU2002253878A1 (en) 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue
US20070020637A1 (en) * 2003-01-21 2007-01-25 Research Association For Biotechnology Full-length cDNA
EP1440981A3 (de) * 2003-01-21 2005-11-23 Research Association for Biotechnology Vollständige humane cDNS
WO2004083366A2 (en) 2003-03-17 2004-09-30 Riikka Lund Methods utilizing novel target genes related to immune-mediated diseases
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088199A2 (en) * 2000-05-18 2001-11-22 Genetics Institute, Llc Identification and modulationof of a t helper-1 and t helper-2 cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"GeneChip Human Genome U133 Set", INTERNET CITATION, XP002232760, Retrieved from the Internet <URL:http://www.affymetrix.com/support/technical/datasheets/hgu133_datashe et.pdf> [retrieved on 20030226] *
DAVID B ALLISON ET AL: "Microarray data analysis: from disarray to consolidation and consensus", NATURE REVIEWS: GENETICS,, vol. 7, no. 1, 1 January 2006 (2006-01-01), pages 55 - 65, XP009100551, ISSN: 1471-0064 *
IWATA MAKOTO ET AL: "Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors.", INTERNATIONAL IMMUNOLOGY AUG 2003, vol. 15, no. 8, August 2003 (2003-08-01), pages 1017 - 1025, XP002548496, ISSN: 0953-8178 *
LUND RIIKKA ET AL: "Identification of novel genes regulated by IL-12, IL-4, or TGF-beta during the early polarization of CD4+ lymphocytes.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 NOV 2003, vol. 171, no. 10, 15 November 2003 (2003-11-15), pages 5328 - 5336, XP002548497, ISSN: 0022-1767 *
O'GARRA A ET AL: "The molecular basis of T helper 1 and T helper 2 cell differentiation.", TRENDS IN CELL BIOLOGY DEC 2000, vol. 10, no. 12, December 2000 (2000-12-01), pages 542 - 550, XP002548498, ISSN: 0962-8924 *

Also Published As

Publication number Publication date
EP1794315A2 (de) 2007-06-13
US7989172B2 (en) 2011-08-02
WO2006030071A3 (en) 2006-05-04
EP2386653A2 (de) 2011-11-16
EP2386653A3 (de) 2012-02-22
WO2006030071A2 (en) 2006-03-23
FI20041204A0 (fi) 2004-09-16
US20080168570A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
AP2006003689A0 (en) Antibodies to MAdCAM
IL189788A0 (en) Human monoclonal antibodies to cd70
DK2066684T3 (da) 5´-Modificerede bicycliske nukleinsyreanaloge
EP1827502A4 (de) Verfahren für die gezielte abgabe von genetischem material an die leber
ZA200900753B (en) Human antibodies to ErbB 2
IL181305A0 (en) Combinations for the treatment of diseases involving cell proliferation
IL218524A0 (en) Compositions and methods relating to novel compounds and targets thereof
IL184734A0 (en) Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
IL183781A0 (en) Pyridine compounds for the treatment of prostaglandin mediated diseases
HUE041957T2 (hu) Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
EP1835074A4 (de) Zusammensetzung für ergiebigkeitsverbesserer
ZA200802641B (en) Human monoclonal antibodies to CD70
GB0500231D0 (en) Compounds which bind to the active site of protein kinase enzymes
EP2139913A4 (de) Einleitung von immunvermitteltem tumorzelltod
EP1889909A4 (de) Verbesserung der widerstandskraft einer pflanze gegenüber krankheiten durch einführung eines transkriptionsfaktor-gens
IL184715A0 (en) Process for the preparation of intermediates
SG137808A1 (en) Improved process for the manufacture of c1 - c4 alkyl (meth) acrylates
EP1765761A4 (de) Neue analoga von 3-o-acetyl-11-keto-beta-boswelliasäure
EP1977003A4 (de) Krankheitsbezogene verfahren und mittel
EP1854881A4 (de) Verfahren zur identifizierung von purkinje-zellen unter verwendung des corl2-gens als ziel
EP1794315A4 (de) Verfahren zur nutzung neuer zielgene in verbindung mit immunvermittelten krankheiten
ZA200704389B (en) Increase in yield by reducing gene expression
EP1721907A4 (de) Silyl-linker für die festphasensynthese von nukleinsäure
IL164850A0 (en) Gene therapy for kidney diseases
AP2007004017A0 (en) Pyridine compounds for the treatment of prostaglandin mediated diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070411

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20091021

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100518